Progress towards a Nordic standard for the investigation of hematuria: 2019.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Skaaheim Haug, Erik
Boström, Peter J
Bjerggaard Jensen, Jørgen
MetadataShow full item record
CitationProgress towards a Nordic standard for the investigation of hematuria: 2019. 2019, 53(1):1-6. doi: 10.1080/21681805.2018.1555187 Scand J Urol
AbstractObjective: To describe the management of patients with hematuria in the Nordic countries in relation to bladder cancer epidemiology, especially in the context of introducing fast track pathways with the aim of proposing a common guideline. Materials and methods: Epidemiological data on bladder cancer from each country, and the combined cancer registry, Nordcan, were analyzed. The evolution of the different national recommendations and the introduction of fast track pathways were assessed. Patients' demographics, type of hematuria and cancer detection rates were analysed if available. Results: The crude incidence of bladder cancer has increased substantially since the 1960s, while the age standardized incidence has been stable during recent decades. The relative survival has increased in all countries, while the mortality has been stable. For those with microscopic hematuria there has been a clear trend towards less rigorous investigations. In the fast track pathways, introduced in three of five countries, about one in five patients with macroscopic hematuria had a cancer diagnosis. Data show that time to diagnosis has been reduced. Conclusions: The number of patients with bladder cancer is increasing in the Nordic region. The introduction of fast track pathways has been important in improving the management of patients with suspicion of the disease. Our recommendation is to focus on macroscopic hematuria in the fast track pathways. Microhematuria without any symptoms should not be an indication for cystoscopy. However, urinary tract symptoms accompanied by microhematuria can still be investigated according to respective guidelines but not necessarily within fast track pathways.
DescriptionTo access publisher's full text version of this article click on the hyperlink below
- Asymptomatic microscopic hematuria as a predictor of neoplasia in the urinary tract.
- Authors: Ordell Sundelin M, Jensen JB
- Issue date: 2017 Oct
- Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
- Authors: Woldu SL, Ng CK, Loo RK, Slezak JM, Jacobsen SJ, Tan WS, Kelly JD, Lough T, Darling D, van Kessel KEM, de Jong JJ, van Criekinge W, Shariat SF, Hiar A, Brown S, Boorjian SA, Barocas DA, Svatek RS, Lotan Y
- Issue date: 2021 May
- Diagnostic and Cost Implications of the 2020 AUA Microhematuria Guidelines: Modeling Impact in a Large Public Health Care System.
- Authors: Gold SA, Kenigsberg AP, Lotan Y
- Issue date: 2022 Jan
- Newly diagnosed bladder cancer: the relationship of initial symptoms, degree of microhematuria and tumor marker status.
- Authors: Boman H, Hedelin H, Jacobsson S, Holmäng S
- Issue date: 2002 Nov
- Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms.
- Authors: Wu JM, Williams KS, Hundley AF, Jannelli ML, Visco AG
- Issue date: 2006 May